CAI Stock Summary and Trading Ideas (Caris Life Sciences | NASDAQ:CAI)

Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

Caris Life Sciences trades on the NASDAQ stock market under the symbol CAI.

As of August 28, 2026, CAI stock price declined to $25.63 with 3,514,884 million shares trading.

CAI has a beta of 2.06, meaning it tends to be more sensitive to market movements. CAI has a correlation of 0.15 to the broad based SPY ETF.

CAI has a market cap of $7.24 billion. This is considered a Mid Cap stock.

Last quarter Caris Life Sciences reported $264 million in Revenue and $.00 earnings per share. This beat revenue expectation by $27 million and missed earnings estimates by -$.01.

The top ETF exchange traded funds that CAI belongs to (by Net Assets): VTI, VB, VBK, IBB, IWP.

CAI has underperformed the market in the last year with a return of -32.9%, while SPY returned +20.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in CAI shares. However, CAI has outperformed the market in the last 3 month and 2 week periods, returning +66.6% and +15.6%, while SPY returned +2.8% and -1.1%, respectively. This indicates CAI has been having a stronger performance recently.

CAI support price is $25.26 and resistance is $27.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAI shares will trade within this expected range on the day.